aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.15372/ATER20180312ateroskleroz-86Research ArticleОБЗОРЫREVIEWSПАТОФИЗИОЛОГИЧЕСКИЕ И КЛИНИЧЕСКИЕ АСПЕКТЫ КАРДИОПРОТЕКЦИИ АТОРВАСТАТИНОМ В ВЫСОКИХ ДОЗАХ У ПАЦИЕНТОВ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМPATHOPHYSIOLOGICAL AND CLINICAL ASPECTS OF HIGH-DOSE ATORVASTATIN CARDIOPROTECTION IN PATIENTS WITH ACUTE CORONARY SYNDROMEАстраханцеваИ. Д.AstrakhantsevaI. D.astrakirina@yandex.ruУрванцеваИ. А.UrvantsevaI. A.noemail@neicon.ruВоробьевА. С.Vorob’YevA. S.noemail@neicon.ruНиколаевК.NikolaevK. Yu.noemail@neicon.ruБУ ХМАО-Югры Окружной кардиологический диспансер «Центр диагностики и сердечно-сосудистой хирургии»; БУ ВО ХМАО-Югры Сургутский государственный университетDistrict Cardiology Clinic Center of Diagnostics and Cardiovascular SurgeryНИИТПМ - филиал ИЦиГ СО РАН; БУ ВО ХМАО-Югры Сургутский государственный университетInstitute of Internal and Preventive Medicine - Branch of Federal Research Institute of Cytology and Genetics of SB RAS; Surgut State University2018270920191437883Copyright © Астраханцева И.Д., Урванцева И.А., Воробьев А.С., Николаев К.Y., 20192019Астраханцева И.Д., Урванцева И.А., Воробьев А.С., Николаев К.Astrakhantseva I.D., Urvantseva I.A., Vorob’Yev A.S., Nikolaev K.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/86

Согласно современным рекомендациям, статины являются неотъемлемой частью лечения острых форм ишемической болезни сердца. Кардиопротекторные эффекты аторвастатина у пациентов с острым коронарным синдромом (ОКС) многогранны и максимально проявляются в высоких дозах. Целью настоящего обзора является анализ данных международной медицинской литературы по применению высоких доз аторвастатина у больных ОКС. Результаты анализа демонстрируют отчетливое снижение сердечно-сосудистых событий в постинфарктном периоде, позитивное воздействие на ключевые патофизиологические процессы при ОКС.

According to modern guidelines, statins are an integral part of treatment of acute coronary heart disease. Cardioprotective effects of atorvastatin in patients with acute coronary syndrome (ACS) are multifaceted and maximally manifested in high doses. The purpose of this review is to analyze international medical literature on the use of high doses of atorvastatin in patients with ACS. The results of the analysis demonstrate significant reduction in post-infarction cardiovascular events, a positive impact on the key pathophysiological processes in ACS.

аторвастатинострый коронарный синдромкардиопротекцияatorvastatinacute coronary syndromecardioprotectionReferencesРабочая группа по реваскуляризации миокарда Европейского общества кардиологов (ESC) и Европеийскоий ассоциации кардиоторакальных хирургов (EACTS). Клинические рекомендации ESC / EACTS по реваскуляризации миокарда 2014 // Рос. кардиол. журн. 2015. С. 5-81.Рабочая группа по реваскуляризации миокарда Европейского общества кардиологов (ESC) и Европеийскоий ассоциации кардиоторакальных хирургов (EACTS). Клинические рекомендации ESC / EACTS по реваскуляризации миокарда 2014 // Рос. кардиол. журн. 2015. С. 5-81.Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия - 2015. Болезни и врожденные аномалии системы кровообращения. М.: НЦССХ им. А.Н. Бакулева, 2016. 212 с.Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия - 2015. Болезни и врожденные аномалии системы кровообращения. М.: НЦССХ им. А.Н. Бакулева, 2016. 212 с.Arbustini E., Grasso M., Diegoli M. et al. Coronary thrombosis in non-cardiac death // Coron. Artery Dis. 1993. Vol. 4. P. 751-759.Arbustini E., Grasso M., Diegoli M. et al. Coronary thrombosis in non-cardiac death // Coron. Artery Dis. 1993. Vol. 4. P. 751-759.Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 15-26.Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 15-26.Matsuzawa Y., Sugiyama S., Sugamura K. et al. Digital assessment of endothelial function and ischemic heart disease in women // J. Am. Coll. Cardiol. 2010. Vol. 55. P. 1688-1696.Matsuzawa Y., Sugiyama S., Sugamura K. et al. Digital assessment of endothelial function and ischemic heart disease in women // J. Am. Coll. Cardiol. 2010. Vol. 55. P. 1688-1696.Halcox J., Schenke W., Zalos G. et al. Prognostic value of coronary vascular endothelial dysfunction // Circulation. 2002. Vol. 106. P. 653-658.Halcox J., Schenke W., Zalos G. et al. Prognostic value of coronary vascular endothelial dysfunction // Circulation. 2002. Vol. 106. P. 653-658.Ulucay A., Demirbag R., Yilmaz R. et al. The relationship between plasma C-reactive protein levels and presence and severity of coronary stenosis in patients with stable angina // Angiology. 2007. Vol. 58. P. 657- 662.Ulucay A., Demirbag R., Yilmaz R. et al. The relationship between plasma C-reactive protein levels and presence and severity of coronary stenosis in patients with stable angina // Angiology. 2007. Vol. 58. P. 657- 662.Pirro M., Bergeron J., Dagenais G. et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men // Arch. Intern. Med. 2001. Vol. 161. P. 2474-2480.Pirro M., Bergeron J., Dagenais G. et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men // Arch. Intern. Med. 2001. Vol. 161. P. 2474-2480.Von Mering G., Arant C., Wessel T. et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute - Sponsored Women’s Ischemia Syndrome Evaluation (WISE) // Circulation. 2004. Vol. 109. P. 722-725.Von Mering G., Arant C., Wessel T. et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute - Sponsored Women’s Ischemia Syndrome Evaluation (WISE) // Circulation. 2004. Vol. 109. P. 722-725.Marzilli M., Merz C., Boden W. et al. Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link! // J. Am. Coll. Cardiol. 2012. Vol. 60, N 1. P. 951-956.Marzilli M., Merz C., Boden W. et al. Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link! // J. Am. Coll. Cardiol. 2012. Vol. 60, N 1. P. 951-956.Третье универсальное определение инфаркта миокарда. Национальные рекомендации Европейского общества кардиологов // Рос. кардиол. журн. 2013. № 2 (100). Прил. 1.Третье универсальное определение инфаркта миокарда. Национальные рекомендации Европейского общества кардиологов // Рос. кардиол. журн. 2013. № 2 (100). Прил. 1.Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J. 2018. Vol. 39, N 2. P. 119-177.Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J. 2018. Vol. 39, N 2. P. 119-177.Schwartz G., Olsson A. Тhe case for intensive statin therapy after acute coronary syndromes // Am. J. Cardiol. 2005. Vol. 96, N 5A. P. 45F-53F.Schwartz G., Olsson A. Тhe case for intensive statin therapy after acute coronary syndromes // Am. J. Cardiol. 2005. Vol. 96, N 5A. P. 45F-53F.Ostadal P. Statins as first-line therapy for acute coronary syndrome? // Exp. Clin. Cardiol. 2012. Vol. 17, N 4. P. 227-236.Ostadal P. Statins as first-line therapy for acute coronary syndrome? // Exp. Clin. Cardiol. 2012. Vol. 17, N 4. P. 227-236.Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival // JAMA. 2001. Vol. 285. P. 430-436.Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival // JAMA. 2001. Vol. 285. P. 430-436.Schiele R., Gitt A., Heer T. Early statin use in acute myocardial is associated with a reduced hospital mortality: Results of the MITRA-2 // Circulation. 2000. Vol. 102 (Suppl. 2). P. 435 (Abst 2117).Schiele R., Gitt A., Heer T. Early statin use in acute myocardial is associated with a reduced hospital mortality: Results of the MITRA-2 // Circulation. 2000. Vol. 102 (Suppl. 2). P. 435 (Abst 2117).Schwartz G., Olsson A., Ezekowitz M. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (the MIRACL study): a randomized controlled trial // JAMA. 2001. Vol. 285. P. 1711-1718.Schwartz G., Olsson A., Ezekowitz M. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (the MIRACL study): a randomized controlled trial // JAMA. 2001. Vol. 285. P. 1711-1718.Ridker P., Cannon C., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. 2005. Vol. 352, N 1. P. 20-28.Ridker P., Cannon C., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. 2005. Vol. 352, N 1. P. 20-28.Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS randomized trial // J. Am. Coll. Cardiol. 2007. Vol. 49. P. 1272-1278.Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS randomized trial // J. Am. Coll. Cardiol. 2007. Vol. 49. P. 1272-1278.Sciascio G., Patti G., Pasceri V. et al. Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial // J. Am. Coll. Cardiol. 2009. Vol. 54. P. 558-565.Sciascio G., Patti G., Pasceri V. et al. Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial // J. Am. Coll. Cardiol. 2009. Vol. 54. P. 558-565.Liu Y., Su Q., Li L. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of nine randomized Controlled Trials // Clin. Cardiol. 2013. Vol. 36, N 12. P. E41-Е48.Liu Y., Su Q., Li L. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of nine randomized Controlled Trials // Clin. Cardiol. 2013. Vol. 36, N 12. P. E41-Е48.Berwanger O., Santucci E., de Barros E. et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial // JAMA. 2018 Vol. 319, N 13. P. 1331-1340.Berwanger O., Santucci E., de Barros E. et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial // JAMA. 2018 Vol. 319, N 13. P. 1331-1340.Kim J., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial // J. Am. Coll. Cardiol. Cardiovasc. Interv. 2010. Vol. 3, N 3. P. 332-339.Kim J., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial // J. Am. Coll. Cardiol. Cardiovasc. Interv. 2010. Vol. 3, N 3. P. 332-339.Priti K., Agrawal A., Ranwa B. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis // Indian Heart J. 2017. Vol. 69, N 4. P. 453-457.Priti K., Agrawal A., Ranwa B. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis // Indian Heart J. 2017. Vol. 69, N 4. P. 453-457.Catapano A. Graham I., de Backer G. et al. 2016 ESC/ EAS Guidelines for the management of Dyslipidaemias // Eur. Heart Journ. 2016. Vol. 37, N 3). P. 2999-3058.Catapano A. Graham I., de Backer G. et al. 2016 ESC/ EAS Guidelines for the management of Dyslipidaemias // Eur. Heart Journ. 2016. Vol. 37, N 3). P. 2999-3058.Li Y., Wang D., Hu C. et al. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta-analysis // Cardiology. 2016. Vol. 135. N 3. P. 188-195.Li Y., Wang D., Hu C. et al. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta-analysis // Cardiology. 2016. Vol. 135. N 3. P. 188-195.Астраханцева И.Д., Урванцева И.А., Николаев К.Ю. Применение внутривенных форм бета-адреноблокаторов при остром коронарном синдроме // Атеросклероз. 2017. Т. 13, № 2. С. 50-54.Астраханцева И.Д., Урванцева И.А., Николаев К.Ю. Применение внутривенных форм бета-адреноблокаторов при остром коронарном синдроме // Атеросклероз. 2017. Т. 13, № 2. С. 50-54.

The authors declare that there are no conflicts of interest present.